Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for acute HF.

Official Title

International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure

Keywords

Acute Heart Failure Registry Heart failure Hospitalized Global Morbidity Mortality Quality of life AHF

Eligibility

You can join if…

Open to people ages 18 years and up

Patients at least 18 years old, or older for those countries where the adult age is above 18 years of age, hospitalized with a primary diagnosis of acute heart failure.

You CAN'T join if...

1-Concomitant participation in any/a clinical trial with any investigational treatment (for any sponsor).

  1. Use of investigational drugs within 5 half-lives of enrollment, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.

Locations

  • Novartis Investigative Site
    San Francisco California 94143-0780 United States
  • Novartis Investigative Site
    San Diego California 92103 United States
  • Novartis Investigative Site
    Vancouver British Columbia V6Z 1Y6 Canada
  • Novartis Investigative Site
    Edmonton Alberta T6G 2B7 Canada
  • Novartis Investigative Site
    Culiacán Sinaloa SN 80230 Mexico
  • Novartis Investigative Site
    Dallas Texas 75390 United States
  • Novartis Investigative Site
    Kansas City Kansas 66160 United States
  • Novartis Investigative Site
    Aguascalientes 20230 Mexico

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Novartis Pharmaceuticals
ID
NCT02595814
Study Type
Observational [Patient Registry]
Last Updated
November 22, 2017